Updated:
Marathon Venture Partners
Marathon Venture Partners is a venture capital fund investing in early to growth stage companies in China's healthcare and fintech sectors. They have made 98...
Marathon Venture Partners
Marathon Venture Partners is a venture capital fund investing in early to growth stage companies in China's healthcare and fintech sectors. They have made 98 investments, including a Series B - II investment in WonderLab on March 02, 2026. The firm has one portfolio exit, AnchorDx, which exited on September 23, 2024.
General information
Firm type
Venture Capital
Year founded
2017
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Beijing
Corporate office
Beijing, China
Sector focus
Frequently asked questions
What is Marathon Venture Partners' investment strategy?
The firm operates as a generalist venture capital investor, participating across the full lifecycle from seed and start-up rounds through late-stage expansion. It targets technology companies in China, with a focus on sectors such as enterprise software and artificial intelligence where founder moats and technical differentiation are strong. The strategy does not appear restricted to a single stage or vertical, allowing flexibility as China's tech landscape shifts.
Is Marathon Venture Partners a US-dollar or renminbi-denominated fund?
Based on its exclusively Beijing presence and the absence of a disclosed offshore parallel structure, the firm is likely structured around renminbi-denominated vehicles serving domestic Chinese limited partners. No US or Singapore entities have been associated with the firm in public filings or official communications, which distinguishes it from the many US-dollar China VC firms that raised international capital during the last decade.
Does Marathon Venture Partners co-invest with other firms?
The firm's co-investment posture is not publicly documented. Given the venture industry's reliance on syndication — particularly in early-stage rounds — participation alongside other domestic Chinese VCs is likely, but no formal co-investor club, GP network, or recurring syndicate partners have been named in available records.
How does an allocator evaluate Marathon Venture Partners given limited public disclosure?
Due diligence would require direct engagement with the firm's partnership, as standard reference points — fund size, track record, team bios, portfolio names — are not in the public domain. An allocator would need to confirm the GP's legal structure, fund-audit history, and LP base in private meetings. The firm's opacity is not unusual among domestic Chinese VC managers, but it demands a higher burden of verification.
What differentiates Marathon Venture Partners from other Beijing-based VCs?
The firm's defining structural feature is its domestic concentration: a single Beijing office, no disclosed US or Singapore vehicle, and a generalist venture mandate that spans seed through late stage. This architecture suits renminbi fundraising and aligns with China's policy preference for onshore investment. For international allocators, however, it means the firm operates almost entirely outside the English-language reporting and data-vendor ecosystem.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: